L2045
Anti-LRP6 (C-terminal region) antibody produced in rabbit
~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-ADCAD2, Anti-Low-density lipoprotein receptor-related protein 6
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~180 kDa
species reactivity
human
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
concentration
~1.5 mg/mL
technique(s)
immunoprecipitation (IP): 10-20 μg using lysate of HEK-293T cells expressing human LRP6
western blot: 1-2 μg/mL using lysate of HEK-293T cells expressing human LRP6
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... LRP6(4040)
mouse ... Lrp6(16974)
General description
Low-density lipoprotein receptor-related protein-6 (LRP6) is expressed primarily in the central nervous system. This protein is made up of three subdomains in the extracellular domain, such as epidermal growth factor (EGF)-like domain, YWTD-type β-propeller domain, and low-density lipoprotein receptor (LDLR) type A (LA) domain. The LRP6 gene is located on the human chromosome at 12p13.2.
Application
Anti-LRP6 (C-terminal region) antibody produced in rabbit may be used in immunoblotting and immunoprecipitation.
Biochem/physiol Actions
Anti-LRP6 (C-terminal region) specifically recognizes human LRP6.
Low-density lipoprotein receptor-related protein-6 (LRP6) is essential for proper brain development. The LRP6 protein forms a Wnt-Frizzled (Fz)-LRP6 complex that recruits axin to the plasma membrane resulting in the inhibition of βcatenin phosphorylation and degradation, and activation of T-cell factor (TCF)/lymphoid enhancer-binding factor-1 (LEF-1)-dependent transcription. Deletion of the LRP6 gene results in severe brain abnormalities. LRP6 also plays a central role in human disease. Mutations in the LRP6 gene are associated with coronary heart disease and osteoporosis.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Preparation Note
Store at –20 °C. For continuous use, the product may be stored at 2–8 °C for up to one month. For extended storage, freeze in working aliquots at –20 °C. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation
Zeng X, et al.
Nature, 438(7069), 873-877 (2005)
Zhihong Cheng et al.
Nature structural & molecular biology, 18(11), 1204-1210 (2011-10-11)
Low-density-lipoprotein (LDL) receptor-related proteins 5 and 6 (LRP5/6) are Wnt co-receptors essential for Wnt/β-catenin signaling. Dickkopf 1 (DKK1) inhibits Wnt signaling by interacting with the extracellular domains of LRP5/6 and is a drug target for multiple diseases. Here we present
LRP6 mutation in a family with early coronary disease and metabolic risk factors
Mani A, et al.
Science (New York, N.Y.), 315(5816), 1278-1282 (2007)
Severe defects in dorsal thalamic development in low-density lipoprotein receptor-related protein-6 mutants
Zhou C J, et al.
The Journal of Neuroscience, 24(35), 7632-7639 (2004)
Adrián Mariño-Enríquez et al.
Human pathology, 39(12), 1844-1848 (2008-07-29)
Congenital mesenchymal tumors are diagnostically challenging as they are rare and may feature overlapping patterns between several benign, low-grade, and tumors of intermediate malignancy, including myofibromatosis, myofibroma/hemangiopericytoma, congenital fibrosarcoma, and inflammatory myofibroblastic tumor. Their immunophenotype is either silent or minimally
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service